Citations

Clear

1434 citation(s) found for "Le, Nathan".

Risk‐Adjusted Comparison of Survival in Chronic Myelomonocytic Leukemia With and Without Allogeneic Stem Cell Transplant: Mayo Clinic Experience in 775 Consecutive Patients
Alsugair, Ali, Fathima, Saubia , Alhousani, Mohammad , Mariotti, E, Bolarinwa, Abiola , Faldu, Priyansh, Yousuf, Muhammad , Foran, James M. , Mangaonkar, Abhishek A. , Litzow, Mark, Sproat, Lisa, Palmer, Jeanne , Matin, Aasiya , Ayala, Ernesto , Slack, James L., Porrata, Luis, Khera, Nandita , Punwani, Nathan , Begna, Kebede H. , Pardanani, Animesh , Gangat, Naseema , Patnaik, Mrinal M. , Tefferi, Ayalew , Gauto‐Mariotti, Estefania , Alsugair, Ali , Alhousani, Mohammad M , Mariotti, Estefania Gauto , Csizmar, Clifford M. , Foran, James M , Mangaonkar, Abhishek A. , Litzow, Mark R. , Murthy, Hemant S , Matin, Aasiya , Ayala, Ernesto , Slack, James, Porrata, Luis , Iqbal, Madiha , Khera, Nandita , Kenderian, Saad Sirop , Chhabra, Saurabh , Pardanani, Animesh , Hogan, William J , Shah, Mithun V , Alkhateeb, Hassan B , Gangat, Naseema , Patnaik, Mrinal , Tefferi, Ayalew , Fathima, Saubia , Bolarinwa, Abiola B , Faldu, Priyansh, Murthy, Hemant S. , Iqbal, Madiha , Kenderian, Saad S. , Chhabra, Saurabh , Hogan, William J. , Shah, Meera , Alkhateeb, Hassan B.

Mayo Clinic

American Journal of Hematology | July 25, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/ajh.70453 | PMID 42499183 Get It

ABSTRACT The recently published BLAST clinical risk model for chronic myelomonocytic leukemia (CMML) and its molecular version (BLAST‐Mol) differentiate low, intermediate, and high‐risk groups. The objective of the current retrospective study was to examine the survival impact of allogeneic stem cell transplant (ASCT) in a consecutive series of Mayo Clinic patients ( n = 775; 68% males, median age 71 years) with CMML, overall and adjusted for baseline BLAST/BLAST‐Mol risk categories. At a median follow‐up of 77 months, 151 (20%) patients underwent ASCT. Overall survival (OS) was longer in the ASCT compared to the non‐ASCT cohorts (median 77 vs. 28 months; p < 0.01). The significant difference in OS between the ASCT and non‐ASCT cohorts was retained after adjusting for BLAST clinical risk groups: high‐risk (median 50 vs. 14 months; p < 0.01), intermediate‐risk (81 vs. 28 months; p < 0.01), and low‐risk (111 vs. 65 months; p = 0.04), respectively. The same was mostly the case when OS comparison was adjusted for BLAST‐Mol with respective p values of < 0.01, < 0.01, and 0.08, respectively. Time‐dependent cox models confirmed the favorable survival impact of ASCT in the BLAST/BLAST‐Mol high‐ and intermediate‐risk groups. The current study highlights the benefit of ASCT for BLAST/BLAST‐Mol high‐ and intermediate‐risk groups in CMML and its potential to overcome the adverse impact of some high risk cytogenetic or molecular abnormalities. These observations support the early use of ASCT in CMML, ideally before BT and regardless of genetic characteristics.
Acute Myeloid Leukemia Subtype‐Specific Prognostic Value of NGS in the Setting of Intensive Chemotherapy
Bolarinwa, Abiola , Al‐Kali, Aref , Mangaonkar, Abhishek A. , Saliba, Antoine N. , Hefazi, Mehrdad , Matin, A, Elliott, Michelle A. , Litzow, Mark R. , Hogan, William J. , Patnaik, Mrinal M. , Pardanani, Animesh , Foran, James M. , Punwani, Nathan , Palmer, Jeanne , Sproat, Lisa Z., Reichard, Kaaren K., He, Rong , Viswanatha, David S., Zepeda‐Mendoza, Cinthya , Gangat, Naseema , Begna, Kebede H. , Tefferi, Ayalew , Saliba, Antoine N. , Alkhateeb, Hassan B , Mangaonkar, Abhishek A. , Saliba, Antoine N , Hefazi, Mehrdad , Elliott, Michelle , Litzow, Mark R. , Hogan, William J , Shah, Mithun V , Patnaik, Mrinal , Pardanani, Animesh , Foran, James M , Badar, Talha , Murthy, Hemant S , Chen, Dong , He, Rong , Zepeda-Mendoza, Cinthya J , Gangat, Naseema , Tefferi, Ayalew , Saliba, Antoine N , Bolarinwa, Abiola B , Alkhateeb, Hassan B. , Shah, Meera , Badar, Talha , Murthy, Hemant S. , Chen, Dong , Reichard, Kaaren K.

Mayo Clinic

American Journal of Hematology | July 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/ajh.70443 | PMID 42470254 Get It

ABSTRACT We examined the prognostic value of routine NGS data in newly diagnosed acute myeloid leukemia (AML) treated with intensive (7 + 3 backbone) induction, specified by AML subtype. A contemporary (2015–2025) series of 545 Mayo Clinic patients (median age 56 years, females 44%) was considered. Median follow‐up was 49 months with 341 (63%) allogeneic hematopoietic stem cell transplantations (AHSCT) recorded. AML subtypes included core‐binding factor (CBF; N = 72; 13%), primary non‐CBF ( N = 403; 74%), post‐myelodysplastic syndromes (MDS) or post‐myelodysplastic/myeloproliferative neoplasms (post‐MDS‐MDS/MPN; N = 28; 5%), post‐MPN ( N = 15; 3%), and therapy‐related (t‐AML; N = 27; 5%). Corresponding complete remission rates, with/without count recovery (CR/CRi), were 89%, 76%, 64%, 27%, and 78% ( p < 0.01) and 5‐year transplant‐censored survival rates 68%, 57%, 21%, 0%, and 55% ( p < 0.01). In multivariable analyses, the prognostic value of specific mutations was mostly limited to primary non‐CBF AML where adverse karyotype (OR 1.9; p = 0.04) predicted inferior and FLT3 ‐ITD (OR 0.4; p < 0.01) or NPM1 MUT / FLT3 WT (OR 0.1; p < 0.01) superior CR/CRi while KRAS MUT (HR 8.8; p < 0.01), TP53 MUT (HR 5.4; p < 0.01), and TET2 MUT (HR 2.3; p = 0.01) predicted inferior and NPM1 MUT / FLT3 WT (HR 0.3; p = 0.01) superior survival. Prognostication in intensively‐treated AML should start with subtype specification and recognition of the limited value of NGS in non‐primary AML. Post‐MPN AML is particularly associated with dismal outcomes and should be prognostically distinguished from post‐MDS‐MDS/MPN AML. In primary non‐CBF AML, in addition to previously established risk factors, the favorable impact of FLT3 ‐ITD on achieving CR/CRi and the unfavorable impact of KRAS MUT and TET2 MUT on transplant‐censored survival were noted and require confirmation from additional studies.
Neuregulin attenuates diaphragm muscle protein degradation via an intricate signaling network
Hellyer, Nathan J., Gransee, Heather M., Sieck, Gary C., Mantilla, Carlos B., Hellyer, Nathan J. , Gransee, Heather M. , Sieck, Gary C. , Mantilla, Carlos B.

Mayo Clinic

Frontiers in Physiology | July 14, 2026 | Volume: 17 | Issue: No issue available | Pages: No page available

10.3389/fphys.2026.1846390 | PMID 42523645 Get It

Introduction The nerve-derived growth factor neuregulin (NRG) plays a role in the regulation of skeletal muscle mass through Akt and mTOR signaling transduction pathways that regulate both protein synthesis and degradation. We previously reported that NRG increases muscle protein synthesis (~20%) in a PI3 kinase (PI3K)/Akt-dependent manner. However, the effects of NRG on protein degradation are still poorly understood and are needed to elucidate the role of NRG in the maintenance of skeletal muscle protein balance. Methods Neonatal diaphragm muscle ex vivo preparations were pharmacologically treated with NRG and pharmacological inhibitors of PI3K (LY294002, 50 μM), MEK (PD98059, 50 μM) or mTOR (rapamycin, 100 nM). Tyrosine release from muscle was used as a surrogate measure of protein degradation. Results We report that basal protein degradation in the neonatal rat diaphragm muscle is significantly reduced by NRG treatment (19%). Basal protein degradation was increased following treatment with inhibitors of PI3K, MEK or mTOR, with inhibition of each pathway sufficient to increase basal protein degradation greater than 30%. Importantly, NRG treatment in the presence of each of these inhibitors blunts the increase in protein degradation induced by inhibition of PI3K, MEK or mTOR. NRG effects were significantly blunted by rapamycin (p &lt; 0.05 compared to NRG alone), but not by LY294002 or PD98059. Discussion We suggest that both the PI3K/Akt and MAP kinase pathways are important for NRG effects on protein degradation, but that mTOR may be a critical modulator of these effects and thus of protein balance in skeletal muscle.
Association of Plasma Neurofilament Light Chain With Diagnostic Classification in a Neuromuscular Referral Cohort
Schipani, Elke , Jones, Felipe J.S. , Bornhorst, Joshua A. , Sorenson, Eric J. , Dubey, Divyanshu , Pinto, Marcus Vinícius , Schipani Bailey, Elke , Staff, Nathan P , Bornhorst, Joshua , Sorenson, Eric , Dubey, Divyanshu , Pinto, Marcus V , Mauermann, Michelle L , Jones, Felipe J S , Staff, Nathan P. , Mauermann, Michelle L.

Mayo Clinic

Neurology | July 13, 2026 | Volume: 107 | Issue: 3 | Pages: No page available

10.1212/wnl.0000000000218304 | PMID 42441926 Get It

Early Versus Late Recurrence in Olfactory Neuroblastoma: A Multi‐Institutional Analysis of Predictive Risk Factors
Harris, Alexandria , Tang, Anthony, Fung, Nicholas , Champagne, Pierre‐Olivier, Fernandez-Miranda, Juan, Gardner, Paul A. , Hwang, Peter H. , Kalyvas, Aristotelis, Patel, Zara M. , Patel, Zara M., Celda, María Peris, Pinheiro-Neto, Carlos D., Sanusi, Olabisi, Thorp, Brian D., Gompel, Jamie J. Van, Zenonos, Georgios, Zwagerman, Nathan T., Bell, Diana, Kuan, Edward C., Geltzeiler, Mathew, Hwang, Peter H , Patel, Zara , Snyderman, Carl H , Wang, Eric W , Choby, Garret , Tang, Anthony , Almeida, João Paulo , Champagne, Pierre‐Olivier , Kalyvas, Aristotelis , Pinheiro‐Neto, Carlos , Sanusi, Olabisi , Thorp, Brian D. , Gompel, Jamie J. Van , Zenonos, Georgios A. , Zwagerman, Nathan T. , Bell, Diana , Kuan, Edward C , Geltzeiler, Mathew , Choby, Garret

Mayo Clinic

International Forum of Allergy & Rhinology | July 9, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/alr.70216 | PMID 42422976 Get It

ABSTRACT Background Olfactory neuroblastoma (ONB) exhibits variable recurrence patterns, with significant late recurrences occurring years after treatment. We investigated cutoff periods to define late recurrence and identified predictors that distinguish patients at risk of late recurrence from those considered cured. Methods From a multi‐institutional cohort of 219 ONB patients treated at nine centers, we analyzed 77 patients with documented recurrence. Using a 48‐month cutoff to define early (< 48 months) versus late (≥ 48 months) recurrence, we evaluated 35 clinical, anatomic, and treatment variables using Firth penalized logistic regression across three comparisons: (1) late versus early recurrence timing, (2) late recurrence versus no recurrence, and (3) early recurrence versus no recurrence. Results Thirty‐four of the 77 (44.2%) recurrences were classified as late. Among the 77 patients who recurred, smaller tumor volume (OR 0.243, p = 0.035) and lower novel Dulguerov staging (OR 0.802, p = 0.038) were associated with late, rather than early recurrence. When patients with late recurrence were compared to those who remained disease‐free, radiographic skull base bone involvement was the strongest independent predictor (OR 2.90, 95% CI 1.14–8.64, p = 0.025), and this effect strengthened after adjusting for tumor volume (OR 3.80, p = 0.029). Pathologic dural invasion (OR 3.29, p = 0.013), Kadish stage (OR 2.02, p = 0.026), and T‐stage (OR 1.32, p = 0.040) were also significant. Conclusions A 48‐month cutoff effectively stratifies ONB recurrence risk. Skull base bone involvement independently predicts recurrence when compared to nonrecurrent cases and uniquely persists as a risk factor for late recurrence. These findings establish skull base bone involvement as a novel biomarker for risk‐stratified surveillance protocols.
AI‐surrogate structure and dose correlation for left anterior descending artery in lung stereotactic body radiotherapy
Chang, Grace, Chen, Quan, Zhu, Libing, Rong, Yi, Yu, Nathan Y., Tao, Randa , Zhu, Libing, Yu, Nathan Y.

Mayo Clinic

Journal of Applied Clinical Medical Physics | July 8, 2026 | Volume: 27 | Issue: 7 | Pages: No page available

10.1002/acm2.70703 | PMID 42418215 Get It

Abstract Background The left anterior descending (LAD) coronary artery is a critical organ‐at‐risk in thoracic radiotherapy. In thoracic stereotactic body radiation therapy (SBRT), sharp dose gradients and poor LAD contrast on 4DCT scans introduce uncertainty in LAD dose assessment. Methods We evaluated the performance of an AI‐generated LAD region structure as a surrogate for manual LAD contours in early‐stage NSCLC. We used deep inspiration breath hold (DIBH) scans from 49 patients with manually delineated LADs; planning risk volume contours were expanded by 3 mm. Then, 96 lung SBRT dose maps were registered by matching the left anterior portion of the heart contours. Dice similarity coefficient (DSC), inclusion ratios (IR), dose–volume histogram (DVH) metrics, linear regression, and linear mixed models were used to compare the structures. The correlation of the AI LAD region and LAD dose to mean heart dose (MHD) was assessed. Results The AI LAD region showed strong correlation with manual LAD contours for maximum dose (D1%, R 2 = 0.93) and volume receiving ≥10 Gy (V10Gy, R 2 = 0.81). The planning risk volume also demonstrated high correlation to the AI LAD region. MHD was a poor predictor of LAD dose ( R 2 ≈0.4). Additional dose metric correlations were assessed. Discussion To investigate dose volume effects to the LAD during radiotherapy for stage I NSCLC, a robust segmentation paradigm must be established. It must be easily implementable on typical imaging acquired during treatment, with an emphasis on clinical translatability. Our model has shown that the AI LAD region has a strong correlation with LAD dose under typical lung SBRT doses and supports its use for further investigation into LAD dose volume constraints during lung SBRT. Conclusion AI LAD region provides a clinically feasible and scalable alternative to manual LAD contouring for dose estimation in lung SBRT. Its strong correlation with key dose metrics validates its use in large‐scale retrospective and prospective studies.
Deep Learning-Based Deblurring for Computed Tomography and a Phantom Evaluation for Coronary Artery Calcium Detectability
Werf, Niels R. van der , Huber, Nathan R., Leiner, Tim , Wuelker, Christian, Schnellbaecher, Nikolas D., Greuter, Marcel J.W. , Graß, Michael , Leiner, Tim , Huber, Nathan R. , Suchá, Dominika , Wülker, Christian , Schnellbächer, Nikolas D.

Mayo Clinic

Journal of Computer Assisted Tomography | July 8, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/rct.0000000000001897 | PMID 42417480 Get It

Introduction: This study aimed to develop and evaluate a deep learning (DL) deblurring algorithm for computed tomography (CT). Phantom testing assessed whether DL deblurring could improve CT image quality and coronary artery calcium (CAC) detectability. Materials and Methods: The algorithm consisted of 2 sequential convolutional neural networks (CNNs): one for denoising and one for deblurring. After deblurring, the estimated noise from the first model was reintroduced to preserve image texture. The CNN denoising model was trained to map high-noise images to routine low-noise ones. The CNN deblurring model was trained using natural images—blurred inputs paired with sharp targets. To assess performance, an anthropomorphic phantom with 100 small calcifications was scanned on a CT system using a CAC scoring protocol. Data were acquired at clinical and high doses, then reconstructed with and without DL deblurring, using 25% of the maximum denoising strength. Detectability was defined as the ability to calculate an Agatston score (≥3 adjacent voxels >130 HU). Results: At high dose, CAC detectability increased from 39% (standard reconstruction) to 48% with deblurring. Similar detectability (39%) was achieved at the routine dose with deblurring, representing a 6% improvement compared with the original routine dose data. Discussion: Quantitative results from phantom testing demonstrate that DL deblurring can improve image quality, based on a clinically relevant, task-based CAC detection metric at clinical dose levels.
A stochastic, physiology-based digital twin model of hemostasis and oxygenation in trauma resuscitation
Vieni, Casey , Iftekharuddin, Anika, Ward, Kevin, Pittman, Roland, Norgan, Andrew, Neal, Matthew, Triulzi, Darrell, Spinella, Phillip, Sperry, J L, Yazer, Mark, Ward, Kevin R. , Seheult, Jansen, Iftekharuddin, Anika, Pittman, Roland Nathan , Spinella, Philip C. , Yazer, Mark H. , Seheult, Jansen N.

Mayo Clinic

No container title available | July 8, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-10273801/v1 | PMID 42466392 Get It

Abstract Hemorrhagic shock is a common emergency that accounts for more than 10% of global mortality and up to 40% of trauma-related mortality. The Advanced Trauma Life Support (ATLS) guidelines outline resuscitation strategies in patients with massive hemorrhage based on clinical trial and observational data. Early intervention with fluids and/or blood products is recommended during resuscitation as key to maintaining vascular patency, stabilizing a patient’s blood pressure, maintaining tissue oxygenation, and limiting shock. From a transfusion perspective, there is wide heterogeneity in the quality of blood products due to donor and manufacturing variation. The optimal transfusion strategy for massive hemorrhage remains unclear. In silico models of resuscitation may offer a means to evaluate the effectiveness and safety of various resuscitation protocols. Here we describe a stochastic multicompartment model of fluid balance and resuscitation that includes (i) cardiovascular hemodynamics, (ii) body fluid compartments and capillary solute exchange, (iii) the ability to alter hemorrhage, resuscitation, and hemostasis parameters, and (iv) tissue oxygenation and capillary-alveolar gas exchange. Building upon deterministic frameworks, this stochastic model more faithfully reflects the clinical heterogeneity of bleeding patients at a level I trauma center. This allows for a proof of concept in silico trial comparing crystalloids, conventional component therapy (CCT), i.e. red cell, platelet and plasma components, to cold-stored low titer group O whole blood (LTOWB). In an in silico cohort of ATLS class III (>30% and ≤40% blood volume lost) hemorrhage, LTOWB resuscitation reduced the time spent in the critical hemostatic window (platelet count <50x109/L, INR≥2, hemoglobin (Hgb) <8 g/dL and fibrinogen <150 mg/dL) compared with CCT (90.59 vs. 147.62 minutes; p=0.04), with no difference in predicted event-free survival (t = 240 minutes; cardiac < 1.5, fluid overload > 10% or SBP > 150% of the starting SBP, or Hgb < 3.0 g/dL). In a separate cohort of ATLS class IV (>40% blood volume lost) hemorrhage, LTOWB yielded a higher predicted event-free survival (74%) versus the CCT arm (69%, p < 0.01). We demonstrate how this in silico platform can function as a digital twin for hemorrhagic trauma enabling precision transfusion strategies, and in parallel, an operational twin to support blood banks to forecast blood product demand and inform massive transfusion protocols and clinical trial design.
Quality and Readability of Websites on Tongue Base Procedures for Pediatric Obstructive Sleep Apnea
Rasmussen, Nathan , Mecham, Jeffrey C. , Scheffler, Patrick , Rasmussen, Nathan G

Mayo Clinic

World Journal of Otorhinolaryngology - Head and Neck Surgery | July 7, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/wjo2.70120 | PMID 42500074 Get It

ABSTRACT Objectives Tongue base obstruction is a cause of persistent sleep apnea after adenotonsillectomy in pediatric patients. The internet is the most used tool by patients for gathering healthcare information. This study aims to assess the quality and readability of websites directed to patients regarding tongue base procedures for pediatric obstructive sleep apnea. Methods Queries for the terms “lingual tonsillectomy,” “posterior midline glossectomy,” “tongue reduction,” “tongue base suspension,” and “hypoglossal nerve stimulator” were entered into Google on September 11, 2023. Thirty sites were pulled for each, and up to 10 sites per query meeting inclusion criteria were included for analysis. The DISCERN tool was used to evaluate quality. Flesch Reading Ease Score (FRES) and Flesch–Kincaid Grade Level (FKGL) were used to measure readability. Sites were analyzed for mention of pediatrics. Results Thirty‐five unique sites were analyzed. The mean DISCERN score was 44.7 (range 28.5–64.0) or “fair.” The mean FRES was 46.3 (range 9.6–66.6) and FKGL 11.5 (range 7.4–19.2), indicating college and 12th‐grade reading levels. Only 8/35 sites mentioned pediatrics. The average number per query of relevant sites directed towards patients on the first search engine page was 3.6. Despite tongue base procedures being relevant to pediatrics, only one in five sites mentioned children. Conclusion Websites directed at patients regarding tongue base procedures are of “fair” quality and at readability grade levels far above what is recommended. The majority of sites available for tongue base procedures are geared to professionals rather than patients. This study demonstrates a need for high‐quality information for patients about these procedures.
High natural variation of BvCR4 homologs in sea beet contrasts with narrow genetic base of sugar beet: Implications for Cercospora leaf spot resistance
Martinez, Ana, Wyatt, Samuel, Neubauer, Jonathan, Reeves, Pat, Richards, Chris, Branch, Eric , Bolton, Melvin, Wyatt, Nathan, Neubauer, Jonathan D., Reeves, Pat, Richards, Christopher M. , Chu, Chenggen , Bolton, Melvin, Wyatt, Nathan A.

Mayo Clinic

Plant Disease | July 7, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1094/pdis-01-26-0161-re | PMID 42410683 Get It

Cercospora leaf spot (CLS) is a destructive disease of sugar beet (Beta vulgaris ssp. vulgaris L.) for which resistance conferred by the gene BvCR4 has been introgressed from sea beet (B. vulgaris ssp. maritima). BvCR4-mediated resistance has been broadly deployed to manage CLS globally in sugar beet; however, continuous implementation exerts strong selection pressure, increasing the risk of disease outbreaks due to resistance-breaking C. beticola populations. This study aimed to identify BvCR4 variants in public B. vulgaris spp. germplasm to assess their genetic and structural diversity. Polymerase chain reaction screening of 589 public B. vulgaris spp. germplasm detected BvCR4 homologs in 32 accessions with diverse responses to CLS including historically relevant sugar beet lines represented in breeding programs and Mediterranean sea beet populations of diverse genetic backgrounds. Analysis of the genomic sequences revealed higher diversity in sea beet compared to sugar beet. Additionally, population genetic analysis indicated that BvCR4 homologs in sugar beet likely originated from sea beet populations in Italy and Greece. We identified historical cultivated materials carrying full proteins encoded by BvCR4 alleles and delineated geographic regions where sea beet populations harbor BvCR4 homologs that may be useful in breeding programs. Structural variation was largely circumscribed within leucine-rich repeat domains, although CLS resistance phenotyping was not associated with specific polymorphisms, suggesting BvCR4-mediated resistance may rely on interactions with other co-receptors. This study provides resources for sugar beet improvement by enabling the identification of BvCR4 homologs in diverse germplasm and disclosing materials with potentially novel resistance.